Drug resistance in leukemia.
D000477:Alkylating Agents / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D007938:Leukemia / Q000188:drug therapy*; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000477:Alkylating Agents; D000963:Antimetabolites; D000970:Antineoplastic Agents; D011687:Purines; D011743:Pyrimidines; D003561:Cytarabine; D003609:Dactinomycin; D014750:Vincristine; D014747:Vinblastine; D004317:Doxorubicin; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin